Terumo (OTCMKTS:TRUMY) Stock Price Up 9.4% – Should You Buy?

Terumo Corp. (OTCMKTS:TRUMY)’s share price rose 9.4% during trading on Thursday. The company traded as high as $16.4950 and last traded at $16.4622. 3,217 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 238,558 shares. The stock had previously closed at $15.05.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Zacks Research raised Terumo from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. Nomura upgraded shares of Terumo from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. Two investment analysts have rated the stock with a Strong Buy rating. Based on data from MarketBeat.com, the company presently has an average rating of “Strong Buy”.

Terumo Trading Up 9.6%

The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.37 and a current ratio of 2.19. The stock has a fifty day moving average of $14.82 and a 200 day moving average of $14.02. The company has a market capitalization of $24.35 billion, a P/E ratio of 23.25 and a beta of 0.82.

Terumo (OTCMKTS:TRUMY) last announced its quarterly earnings results on Friday, August 7th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.17 by $0.13. The business had revenue of $1.97 billion for the quarter, compared to analysts’ expectations of $1.84 billion. Terumo had a net margin of 13.83% and a return on equity of 10.44%. As a group, equities research analysts anticipate that Terumo Corp. will post 0.86 EPS for the current fiscal year.

Terumo Company Profile

Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells medical devices and healthcare products. Its offerings support hospitals, physicians and other healthcare providers across areas including cardiovascular care, interventional procedures, blood management, cell and gene therapies, and general medical care.

The company’s products include catheters, guidewires, stents and other devices used in cardiovascular and endovascular procedures, as well as blood bags, apheresis systems, cell-processing technologies, infusion and injection products, and hospital equipment.